Literature DB >> 17965219

TMPRSS2-ETS fusion prostate cancer: biological and clinical implications.

Francesca Demichelis1, Mark A Rubin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17965219      PMCID： PMC2095481          DOI： 10.1136/jcp.2007.046557

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN： 0021-9746            Impact factor:   3.411


× No keyword cloud information.
  22 in total

1.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

Authors:  Scott A Tomlins; Daniel R Rhodes; Sven Perner; Saravana M Dhanasekaran; Rohit Mehra; Xiao-Wei Sun; Sooryanarayana Varambally; Xuhong Cao; Joelle Tchinda; Rainer Kuefer; Charles Lee; James E Montie; Rajal B Shah; Kenneth J Pienta; Mark A Rubin; Arul M Chinnaiyan
Journal:  Science       Date:  2005-10-28       Impact factor: 47.728

2.  Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer.

Authors:  Maria Johansson Soller; Margareth Isaksson; Peter Elfving; Wolfgang Soller; Rolf Lundgren; Ioannis Panagopoulos
Journal:  Genes Chromosomes Cancer       Date:  2006-07       Impact factor: 5.006

3.  Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program.

Authors:  Matthew J Hayat; Nadia Howlader; Marsha E Reichman; Brenda K Edwards
Journal:  Oncologist       Date:  2007-01

4.  10q23.3 loss of heterozygosity is higher in lymph node-positive (pT2-3,N+) versus lymph node-negative (pT2-3,N0) prostate cancer.

Authors:  M A Rubin; A Gerstein; K Reid; D G Bostwick; L Cheng; R Parsons; N Papadopoulos
Journal:  Hum Pathol       Date:  2000-04       Impact factor: 3.466

5.  Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer.

Authors:  Brett S Carver; Fernando J Bianco; Peter T Scardino; James A Eastham
Journal:  J Urol       Date:  2006-08       Impact factor: 7.450

6.  25-year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series.

Authors:  Christopher R Porter; Koichi Kodama; Robert P Gibbons; Roy Correa; Felix K-H Chun; Paul Perrotte; Pierre I Karakiewicz
Journal:  J Urol       Date:  2006-08       Impact factor: 7.450

7.  TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.

Authors:  Scott A Tomlins; Rohit Mehra; Daniel R Rhodes; Lisa R Smith; Diane Roulston; Beth E Helgeson; Xuhong Cao; John T Wei; Mark A Rubin; Rajal B Shah; Arul M Chinnaiyan
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

8.  Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome.

Authors:  Gyorgy Petrovics; Aijun Liu; Syed Shaheduzzaman; Bungo Furusato; Bungo Furasato; Chen Sun; Yongmei Chen; Martin Nau; Lakshmi Ravindranath; Yidong Chen; Albert Dobi; Vasantha Srikantan; Isabell A Sesterhenn; David G McLeod; Maryanne Vahey; Judd W Moul; Shiv Srivastava
Journal:  Oncogene       Date:  2005-05-26       Impact factor: 9.867

9.  How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden.

Authors:  Ove Andrén; Katja Fall; Lennart Franzén; Swen-Olof Andersson; Jan-Erik Johansson; Mark A Rubin
Journal:  J Urol       Date:  2006-04       Impact factor: 7.450

10.  The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy.

Authors:  John F Ward; Michael L Blute; Jeffrey Slezak; Erik J Bergstralh; Horst Zincke
Journal:  J Urol       Date:  2003-11       Impact factor: 7.450
View more
  19 in total

Review 1.  Molecular subtyping of prostate cancer.

Authors:  Samuel D Kaffenberger; Christopher E Barbieri
Journal:  Curr Opin Urol       Date:  2016-05       Impact factor: 2.309

2.  Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.

Authors:  Scott A Tomlins; Mohammed Alshalalfa; Elai Davicioni; Nicholas Erho; Kasra Yousefi; Shuang Zhao; Zaid Haddad; Robert B Den; Adam P Dicker; Bruce J Trock; Angelo M DeMarzo; Ashley E Ross; Edward M Schaeffer; Eric A Klein; Cristina Magi-Galluzzi; R Jeffrey Karnes; Robert B Jenkins; Felix Y Feng
Journal:  Eur Urol       Date:  2015-05-08       Impact factor: 20.096

Review 3.  Emergence of the Noncoding Cancer Genome: A Target of Genetic and Epigenetic Alterations.

Authors:  Stanley Zhou; Aislinn E Treloar; Mathieu Lupien
Journal:  Cancer Discov       Date:  2016-10-19       Impact factor: 39.397

4.  Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay.

Authors:  Francesco Orlando; Alessandro Romanel; Blanca Trujillo; Michael Sigouros; Daniel Wetterskog; Orsetta Quaini; Gianmarco Leone; Jenny Z Xiang; Anna Wingate; Scott Tagawa; Anuradha Jayaram; Mark Linch; Mariam Jamal-Hanjani; Charles Swanton; Mark A Rubin; Alexander W Wyatt; Himisha Beltran; Gerhardt Attard; Francesca Demichelis
Journal:  NAR Cancer       Date:  2022-05-27

5.  TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation.

Authors:  C Sun; A Dobi; A Mohamed; H Li; R L Thangapazham; B Furusato; S Shaheduzzaman; S-H Tan; G Vaidyanathan; E Whitman; D J Hawksworth; Y Chen; M Nau; V Patel; M Vahey; J S Gutkind; T Sreenath; G Petrovics; I A Sesterhenn; D G McLeod; S Srivastava
Journal:  Oncogene       Date:  2008-06-09       Impact factor: 9.867

6.  Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer.

Authors:  Julie L Kasperzyk; Stephen P Finn; Richard Flavin; Michelangelo Fiorentino; Rosina Lis; Whitney K Hendrickson; Steven K Clinton; Howard D Sesso; Edward L Giovannucci; Meir J Stampfer; Massimo Loda; Lorelei A Mucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-10-15       Impact factor: 4.254

7.  A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer.

Authors:  Dean A Troyer; Tamara Jamaspishvili; Wei Wei; Ziding Feng; Jennifer Good; Sarah Hawley; Ladan Fazli; Jesse K McKenney; Jeff Simko; Antonio Hurtado-Coll; Peter R Carroll; Martin Gleave; Raymond Lance; Daniel W Lin; Peter S Nelson; Ian M Thompson; Lawrence D True; James D Brooks; Jeremy A Squire
Journal:  Prostate       Date:  2015-05-04       Impact factor: 4.104

8.  Dose-dependent effects of small-molecule antagonists on the genomic landscape of androgen receptor binding.

Authors:  Zhou Zhu; Manli Shi; Wenyue Hu; Heather Estrella; Jon Engebretsen; Tim Nichols; David Briere; Natilie Hosea; Gerrit Los; Paul A Rejto; Andrea Fanjul
Journal:  BMC Genomics       Date:  2012-07-31       Impact factor: 3.969

Review 9.  Prostate cancer stem cells.

Authors:  S H Lang; F M Frame; A T Collins
Journal:  J Pathol       Date:  2009-01       Impact factor: 7.996

10.  The relationship between chimeric RNAs and gene fusions: Potential implications of reciprocity in cancer.

Authors:  Justin Elfman; Lam-Phong Pham; Hui Li
Journal:  J Genet Genomics       Date:  2020-06-14       Impact factor: 5.723
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.